Your shopping cart is currently empty

EGFR-IN-45 is a potent pan-inhibitor of the epidermal growth factor receptor (EGFR) with an IC50 of 0.4 μM and also targets CDK2 with an IC50 of 1.6 μM. It inhibits topoisomerases Topo I and Topo II, blocks the cancer cell cycle in the pre-G1 phase, and induces apoptosis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | 10-14 weeks | 10-14 weeks | |
| 50 mg | $1,980 | 10-14 weeks | 10-14 weeks | |
| 100 mg | $2,500 | 10-14 weeks | 10-14 weeks |
| Description | EGFR-IN-45 is a potent pan-inhibitor of the epidermal growth factor receptor (EGFR) with an IC50 of 0.4 μM and also targets CDK2 with an IC50 of 1.6 μM. It inhibits topoisomerases Topo I and Topo II, blocks the cancer cell cycle in the pre-G1 phase, and induces apoptosis. |
| Targets&IC50 | CDK2:1.6 μM, EGFR:0.4 μM |
| Molecular Weight | 473.53 |
| Formula | C28H23N7O |
| Smiles | #N/A |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.